Brief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
17/06/2026 21:15
BRIEF-Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026 June 17 (Reuters) - Alkermes Plc ALKS.O:
ALKERMES PRESENTS DETAILED POSITIVE RESULTS FROM VIBRANCE-2 PHASE 2 STUDY OF ALIXOREXTON IN ADULTS WITH NARCOLEPSY TYPE 2 AT SLEEP 2026
Source text: ID:nBw72Ppdna
Further company coverage: ALKS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes